BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Madness to 'Method' Ruling? Time Will Tell in Myriad Case
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Madness to 'Method' Ruling? Time Will Tell in Myriad Case
April 5, 2010
By
Randy Osborne
No Comments
With last week's federal ruling that invalidated Myriad Genetics Inc.'s patent claims on BRCA1 and BRCA2 genes, all eyes are on the appeals court, even as pundits continue to speculate what an ultimate, irrevocable decision either way might mean.
BioWorld